USPTO serial 99658639
MENDRA
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- HUSSAIN, TASNEEM
- Law office
- TMO LAW OFFICE 118
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MENDRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark A. Jansen
Mark A. Jansen Fenwick & West LLP801 California StreetSilicon Valley CenterMountain View, CA 94041Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances; therapeutic and prophylactic pharmaceutical products; medicines for the treatment and prevention of rare diseases, autoimmune diseases, inflammatory diseases, and infectious diseases and disorders; pharmaceutical products for use in medical research and clinical development; pharmaceutical products in development for regulatory approval | ACTIVE | — |
| 009 | downloadable artificial intelligence software for use with rare diseases; downloadable artificial intelligence software for use in the field of medicine and medical research; downloadable artificial intelligence (AI) software for use in pharmaceutical research, drug discovery, clinical development, regulatory analysis, data analysis, and commercialization; downloadable software for collecting, analyzing, searching, and managing biomedical, clinical, and scientific data; downloadable software platforms for identifying, evaluating, and developing pharmaceutical and therapeutic assets, including software for rare disease research; downloadable software for identifying and recruiting clinical trial participants; downloadable software for managing global regulatory submissions and market access data; downloadable software for mapping and forecasting rare disease populations; downloadable software for facilitating real-time collaboration in pharmaceutical development and commercialization; downloadable artificial intelligence software for developing treatments and drugs for treating rare diseases | ACTIVE | — |
| 042 | Scientific research and development services in the fields of pharmaceuticals, therapeutics, and medicine; research and development of pharmaceutical products, therapies, and treatments; biomedical research services; pharmaceutical research and clinical development services; providing online non-downloadable software artificial intelligence software for use with rare diseases; providing online non-downloadable software artificial intelligence software for use in the field of medicine and medical research; providing online non-downloadable software artificial intelligence (AI) software for use in pharmaceutical research, drug discovery, clinical development, regulatory analysis, data analysis, and commercialization; providing online non-downloadable software for collecting, analyzing, searching, and managing biomedical, clinical, and scientific data; providing online non-downloadable software for identifying, evaluating, and developing pharmaceutical and therapeutic assets, including software for rare disease research; providing non-downloadable artificial intelligence software for use in pharmaceutical research, rare disease analysis, asset evaluation, clinical development, and commercialization; providing online non-downloadable software for searching, aggregating, analyzing, and modeling biomedical, clinical, and pharmaceutical data; providing temporary use of online, non-downloadable software for identifying and recruiting clinical trial participants; providing temporary use of online, non-downloadable software for managing global regulatory submissions and market access data; providing temporary use of online, non-downloadable software for mapping and forecasting rare disease populations; providing temporary use of online, non-downloadable software for facilitating real-time collaboration in pharmaceutical development and commercialization; providing temporary use of online, non-downloadable artificial intelligence software for developing treatments and drugs for treating rare diseases | ACTIVE | — |
| 044 | Medical research and development services; providing medical and scientific information in the field of rare diseases; providing health and medical information relating to diseases, disorders, diagnosis, treatment, and prevention; medical advisory services relating to pharmaceutical research and development; Consulting services in the field of rare disease drug development; Prevention, diagnostics, treatment, and therapy for rare diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 23, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 23, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 16, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 18, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 18, 2026 | NWAP | NEW APPLICATION ENTERED | — |